A phase 2 trial of Memo Therapeutics’ kidney transplant drug candidate has missed its primary endpoint, adding to the list of ...

Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new small ...

The orthopedic implant maker Shoulder Innovations is the latest medtech to plan for a nine-figure IPO, as it looks to scale ...

Adicet Bio is handing out pink slips to 30% of its staffers in tandem with a pipeline restructure that includes discontinuing ...

The company’s TYK2 inhibitor GLPG3667 sits on the chopping block as well. Galapagos is “actively exploring partnership ...

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

Australian life sciences venture capital firm Brandon Capital has closed its largest fund yet, raising A$439 million (about ...

The clinical diagnostic developer Trinity Biotech intends to enter the personal diabetes management market, with a planned ...

Rocket Pharmaceuticals is laying off 30% of its staff and focusing on its cardiovascular disease programs, causing delays to ...